Polyamine Metabolism for Drug Intervention in Trypanosomatids

Neglected tropical diseases transmitted by trypanosomatids include three major human scourges that globally affect the world’s poorest people: African trypanosomiasis or sleeping sickness, American trypanosomiasis or Chagas disease and different types of leishmaniasis. Different metabolic pathways have been targeted to find antitrypanosomatid drugs, including polyamine metabolism. Since their discovery, the naturally occurring polyamines, putrescine, spermidine and spermine, have been considered important metabolites involved in cell growth. With a complex metabolism involving biosynthesis, catabolism and interconversion, the synthesis of putrescine and spermidine was targeted by thousands of compounds in an effort to produce cell growth blockade in tumor and infectious processes with limited success. However, the discovery of eflornithine (DFMO) as a curative drug against sleeping sickness encouraged researchers to develop new molecules against these diseases. Polyamine synthesis inhibitors have also provided insight into the peculiarities of this pathway between the host and the parasite, and also among different trypanosomatid species, thus allowing the search for new specific chemical entities aimed to treat these diseases and leading to the investigation of target-based scaffolds. The main molecular targets include the enzymes involved in polyamine biosynthesis (ornithine decarboxylase, S-adenosylmethionine decarboxylase and spermidine synthase), enzymes participating in their uptake from the environment, and the enzymes involved in the redox balance of the parasite. In this review, we summarize the research behind polyamine-based treatments, the current trends, and the main challenges in this field.

[1]  Rajiv Kumar,et al.  Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination , 2023, Frontiers in immunology.

[2]  A. Edkins,et al.  Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies , 2023, International journal of molecular sciences.

[3]  J. van Griensven,et al.  The status of combination therapy for visceral leishmaniasis: an updated review. , 2023, The Lancet. Infectious diseases.

[4]  T. Agampodi,et al.  The stigma associated with cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL): A protocol for a systematic review , 2023, PloS one.

[5]  A. Hofer Targeting the nucleotide metabolism of Trypanosoma brucei and other trypanosomatids , 2023, FEMS microbiology reviews.

[6]  Ancheng C. Huang,et al.  Conformational cycle of human polyamine transporter ATP13A2 , 2023, Nature Communications.

[7]  Adarsh Vardhan Tangella,et al.  Difluoromethylornithine (DFMO) and Neuroblastoma: A Review , 2023, Cureus.

[8]  Y. Pérez-Pertejo,et al.  Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates , 2023, Biomolecules.

[9]  S. Montgomery,et al.  Chagas Disease , 2023, Annals of Internal Medicine.

[10]  A. Ilari,et al.  Inhibition of Leishmania infantum Trypanothione Reductase by New Aminopropanone Derivatives Interacting with the NADPH Binding Site , 2023, Molecules.

[11]  Y. Pérez-Pertejo,et al.  Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis , 2023, International journal of molecular sciences.

[12]  Lucas N. Alberca,et al.  A combined ligand and target-based virtual screening strategy to repurpose drugs as putrescine uptake inhibitors with trypanocidal activity , 2022, Journal of Computer-Aided Molecular Design.

[13]  David Shum,et al.  Discovery of novel Leishmania major trypanothione synthetase inhibitors by high-throughput screening. , 2022, Biochemical and biophysical research communications.

[14]  E. Bottieau,et al.  Gambiense human African trypanosomiasis: the bumpy road to elimination , 2022, Current opinion in infectious diseases.

[15]  Prof Vikas Kumar,et al.  - Amphotericin B: A drug of choice for Visceral Leishmaniasis. , 2022, Acta tropica.

[16]  Surbhi Jain,et al.  Metabolic Pathways of Leishmania Parasite: Source of Pertinent Drug Targets and Potent Drug Candidates , 2022, Pharmaceutics.

[17]  Pravindra Kumar,et al.  Biophysical and modeling-based approach for the identification of inhibitors against DOHH from Leishmania donovani. , 2022, Briefings in functional genomics.

[18]  A. Ilari,et al.  Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design , 2022, Frontiers in Molecular Biosciences.

[19]  P. Chiodini,et al.  Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas , 2022, Research and reports in tropical medicine.

[20]  N. Carter,et al.  Polyamine Metabolism in Leishmania Parasites: A Promising Therapeutic Target , 2022, Medical sciences.

[21]  David Shum,et al.  Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening , 2022, Journal of enzyme inhibition and medicinal chemistry.

[22]  H. Bergman,et al.  Chemotherapy for second‐stage human African trypanosomiasis: drugs in use , 2021, The Cochrane database of systematic reviews.

[23]  J. Beijnen,et al.  An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. , 2021, International journal of antimicrobial agents.

[24]  T. Mavromoustakos,et al.  An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases , 2021, Molecules.

[25]  M. Meenu,et al.  The discovery of indolone GW5074 during a comprehensive search for non-polyamine-based polyamine transport inhibitors. , 2021, The international journal of biochemistry & cell biology.

[26]  C. Baroukh,et al.  Polyamines: double agents in disease and plant immunity. , 2021, Trends in plant science.

[27]  A. Kopylov,et al.  The Concept of Folic Acid in Health and Disease , 2021, Molecules.

[28]  J. Albrecht,et al.  Roles of nitric oxide and polyamines in brain tumor growth. , 2021, Advances in medical sciences.

[29]  Rachel Tidman,et al.  The impact of climate change on neglected tropical diseases: a systematic review , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  M. Bijlmakers Ubiquitination and the Proteasome as Drug Targets in Trypanosomatid Diseases , 2021, Frontiers in Chemistry.

[31]  O. Singh,et al.  Domestic Mammals as Reservoirs for Leishmania donovani on the Indian Subcontinent: Possibility and Consequences on Elimination. , 2020, Transboundary and emerging diseases.

[32]  V. Baekelandt,et al.  ATP13A3 is a major component of the enigmatic mammalian polyamine transport system , 2020, The Journal of biological chemistry.

[33]  C. Robello,et al.  Trypanothione metabolism as Drug Target for Trypanosomatids. , 2020, Current pharmaceutical design.

[34]  P. Z. Ramos,et al.  Structural features and development of an assay platform of the parasite target deoxyhypusine synthase of Brugia malayi and Leishmania major , 2020, PLoS neglected tropical diseases.

[35]  R. Banerjee,et al.  In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis , 2020, PLoS neglected tropical diseases.

[36]  F. Supek,et al.  Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases , 2020, Journal of medicinal chemistry.

[37]  S. Raj,et al.  An overview of biochemically characterized drug targets in metabolic pathways of Leishmania parasite , 2020, Parasitology Research.

[38]  S. Harper,et al.  Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme , 2020, PLoS neglected tropical diseases.

[39]  Zhong-dao Wu,et al.  Human African trypanosomiasis: the current situation in endemic regions and the risks for non-endemic regions from imported cases , 2020, Parasitology.

[40]  Sen Liu,et al.  Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy , 2020, Frontiers in Pharmacology.

[41]  S. Pantano,et al.  Mechanistic and biological characterisation of novel N5-substituted paullones targeting the biosynthesis of trypanothione in Leishmania , 2020, Journal of enzyme inhibition and medicinal chemistry.

[42]  Chantal Reigada,et al.  Identification of Trypanosoma cruzi Polyamine Transport Inhibitors by Computational Drug Repurposing , 2019, Front. Med..

[43]  L. Tilley,et al.  The proteasome as a target for protozoan parasites , 2019, Expert opinion on therapeutic targets.

[44]  C. García-Estrada,et al.  DNA Topoisomerases of Leishmania parasites; druggable targets for drug discovery. , 2019, Current medicinal chemistry.

[45]  R. Castillo,et al.  Leishmania mexicana Trypanothione Reductase Inhibitors: Computational and Biological Studies , 2019, Molecules.

[46]  S. Croft,et al.  Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis , 2019, International journal for parasitology. Drugs and drug resistance.

[47]  S. Sundar,et al.  Current and emerging medications for the treatment of leishmaniasis , 2019, Expert opinion on pharmacotherapy.

[48]  M. Gramiccia,et al.  Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism , 2019, Amino Acids.

[49]  Maria Paola Costi,et al.  Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors. , 2019, ACS infectious diseases.

[50]  M. Phillips,et al.  Trypanosomatid Deoxyhypusine Synthase Activity Is Dependent on Shared Active-Site Complementation between Pseudoenzyme Paralogs. , 2018, Structure.

[51]  A. Pegg Introduction to the Thematic Minireview Series: Sixty plus years of polyamine research , 2018, The Journal of Biological Chemistry.

[52]  M. Phillips Polyamines in protozoan pathogens , 2018, The Journal of Biological Chemistry.

[53]  M. Phillips,et al.  A dual regulatory circuit consisting of S-adenosylmethionine decarboxylase protein and its reaction product controls expression of the paralogous activator prozyme in Trypanosoma brucei , 2018, PLoS pathogens.

[54]  A. Pegg,et al.  Polyamine metabolism and cancer: treatments, challenges and opportunities , 2018, Nature Reviews Cancer.

[55]  I. Felzenszwalb,et al.  Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity , 2018, Antimicrobial Agents and Chemotherapy.

[56]  S. Sundar,et al.  Emerging therapeutic targets for treatment of leishmaniasis , 2018, Expert opinion on therapeutic targets.

[57]  S. Burza,et al.  Leishmaniasis , 2018, The Lancet.

[58]  M. Booth Climate Change and the Neglected Tropical Diseases , 2018, Advances in Parasitology.

[59]  A. M. Carvalho,et al.  The Elderly Respond to Antimony Therapy for Cutaneous Leishmaniasis Similarly to Young Patients but Have Severe Adverse Reactions. , 2018, The American journal of tropical medicine and hygiene.

[60]  Chantal Reigada,et al.  Targeting polyamine transport in Trypanosoma cruzi. , 2018, European journal of medicinal chemistry.

[61]  N. LoGiudice,et al.  Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases , 2018, Medical sciences.

[62]  L. Floeter-Winter,et al.  Arginine and Polyamines Fate in Leishmania Infection , 2018, Front. Microbiol..

[63]  M. Phillips,et al.  Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase. , 2018, Journal of medicinal chemistry.

[64]  S. Sundar,et al.  Chemotherapeutics of visceral leishmaniasis: present and future developments , 2017, Parasitology.

[65]  L. Floeter-Winter,et al.  Arginase expression modulates nitric oxide production in Leishmania (Leishmania) amazonensis , 2017, PloS one.

[66]  T. E. Richardson,et al.  Synthesis and evaluation of analogs of 5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine (MDL 73811, or AbeAdo) - An inhibitor of S-adenosylmethionine decarboxylase with antitrypanosomal activity. , 2017, Bioorganic & medicinal chemistry.

[67]  D. Horn,et al.  Ornithine uptake and the modulation of drug sensitivity in Trypanosoma brucei , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  T. E. Richardson,et al.  Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay. , 2017, ACS infectious diseases.

[69]  A. Errasti,et al.  Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid Transporters in Trypanosoma cruzi , 2017, PLoS neglected tropical diseases.

[70]  D. Boykin,et al.  In Vitro, Ex Vivo, and In Vivo Activities of Diamidines against Trypanosoma congolense and Trypanosoma vivax , 2017, Antimicrobial Agents and Chemotherapy.

[71]  A. Iglesias,et al.  Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase. , 2017, European journal of medicinal chemistry.

[72]  N. Grishin,et al.  Relief of autoinhibition by conformational switch explains enzyme activation by a catalytically dead paralog , 2016, eLife.

[73]  P. Yates,et al.  Arginase Is Essential for Survival of Leishmania donovani Promastigotes but Not Intracellular Amastigotes , 2016, Infection and Immunity.

[74]  Glen Spraggon,et al.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.

[75]  A. Aly,et al.  Plasmodium AdoMetDC/ODC bifunctional enzyme is essential for male sexual stage development and mosquito transmission , 2016, Biology Open.

[76]  P. Yates,et al.  The Polyamine Pathway of Leishmania donovani as a Potential Therapeutic Target , 2016, The FASEB Journal.

[77]  S. Sundar,et al.  Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani , 2016, Front. Microbiol..

[78]  Darío E. Balcazar,et al.  Trypanosoma cruzi Polyamine Transporter: Its Role on Parasite Growth and Survival Under Stress Conditions , 2016, The Journal of Membrane Biology.

[79]  V. Dubey,et al.  Novel Inhibitors of Ornithine Decarboxylase of Leishmania Parasite (LdODC): The Parasite Resists LdODC Inhibition by Overexpression of Spermidine Synthase , 2016, Chemical biology & drug design.

[80]  Alan Talevi,et al.  Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning , 2016, Journal of Computer-Aided Molecular Design.

[81]  D. Leaver,et al.  Fluorinated Sterols Are Suicide Inhibitors of Ergosterol Biosynthesis and Growth in Trypanosoma brucei. , 2015, Chemistry & biology.

[82]  T. Niimi,et al.  Structural insights into the novel inhibition mechanism of Trypanosoma cruzi spermidine synthase. , 2015, Acta crystallographica. Section D, Biological crystallography.

[83]  Sushma R. Singh,et al.  Antileishmanial effect of mevastatin is due to interference with sterol metabolism , 2015, Parasitology Research.

[84]  M. Miles,et al.  Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease , 2015, Expert review of anti-infective therapy.

[85]  Megan P. Miller,et al.  Identification and functional characterization of a novel arginine/ornithine transporter, a member of a cationic amino acid transporter subfamily in the Trypanosoma cruzi genome , 2015, Parasites & Vectors.

[86]  J. Correa-Basurto,et al.  Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents. , 2015, European journal of medicinal chemistry.

[87]  Jorge González,et al.  Role of the Ubiquitin-Proteasome Systems in the Biology and Virulence of Protozoan Parasites , 2015, BioMed research international.

[88]  J. Pratap,et al.  Novel protein-protein interaction between spermidine synthase and S-adenosylmethionine decarboxylase from Leishmania donovani. , 2015, Biochemical and biophysical research communications.

[89]  M. Barrett,et al.  Crystal Structure of an Arginase-like Protein from Trypanosoma brucei That Evolved without a Binuclear Manganese Cluster , 2014, Biochemistry.

[90]  C. García-Estrada,et al.  Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery , 2014, International journal for parasitology. Drugs and drug resistance.

[91]  S. Sundar,et al.  Characterization of Glycolytic Enzymes - rAldolase and rEnolase of Leishmania donovani, Identified as Th1 Stimulatory Proteins, for Their Immunogenicity and Immunoprophylactic Efficacies against Experimental Visceral Leishmaniasis , 2014, PloS one.

[92]  Montserrat G. Vásquez-Valdivieso,et al.  Identification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase. , 2014, ACS medicinal chemistry letters.

[93]  R. B. Giordani,et al.  Assessment of Leishmanicidal and Trypanocidal Activities of Aliphatic Diamine Derivatives , 2013, Chemical biology & drug design.

[94]  H. Wallace,et al.  Polyamines and membrane transporters , 2013, Amino Acids.

[95]  M. Phillips,et al.  Product feedback regulation implicated in translational control of the Trypanosoma brucei S‐adenosylmethionine decarboxylase regulatory subunit prozyme , 2013, Molecular microbiology.

[96]  M. Strauss,et al.  Use of clomipramine as chemotherapy of the chronic phase of Chagas disease , 2013, Parasitology.

[97]  A. Fairlamb,et al.  Allosteric Activation of Trypanosomatid Deoxyhypusine Synthase by a Catalytically Dead Paralog , 2013, The Journal of Biological Chemistry.

[98]  C. Rock,et al.  Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas , 2013, British Journal of Cancer.

[99]  M. Phillips,et al.  Trypanosoma brucei S-Adenosylmethionine Decarboxylase N Terminus Is Essential for Allosteric Activation by the Regulatory Subunit Prozyme* , 2013, The Journal of Biological Chemistry.

[100]  N. Carter,et al.  Purine salvage in Leishmania: complex or simple by design? , 2012, Trends in parasitology.

[101]  Michael P. Barrett,et al.  Untargeted Metabolomics Reveals a Lack Of Synergy between Nifurtimox and Eflornithine against Trypanosoma brucei , 2012, PLoS neglected tropical diseases.

[102]  L. Floeter-Winter,et al.  Leishmania amazonensis Arginase Compartmentalization in the Glycosome Is Important for Parasite Infectivity , 2012, PloS one.

[103]  R. Madhubala,et al.  A Unique Modification of the Eukaryotic Initiation Factor 5A Shows the Presence of the Complete Hypusine Pathway in Leishmania donovani , 2012, PloS one.

[104]  Y. Pérez-Pertejo,et al.  Role of trypanosomatid's arginase in polyamine biosynthesis and pathogenesis. , 2012, Molecular and biochemical parasitology.

[105]  B. Miniscalco,et al.  Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum , 2012, Parasitology Research.

[106]  V. Dubey,et al.  Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from Leishmania donovani , 2011, Biological chemistry.

[107]  T. Vickers,et al.  Folate metabolic pathways in Leishmania. , 2011, Essays in biochemistry.

[108]  P. Fernandes,et al.  Mechanism of formation of the internal aldimine in pyridoxal 5'-phosphate-dependent enzymes. , 2011, Journal of the American Chemical Society.

[109]  Y. Pérez-Pertejo,et al.  Leishmania donovani: proteasome-mediated down-regulation of methionine adenosyltransferase , 2011, Parasitology.

[110]  B. Ullman,et al.  Spermidine Synthase Is Required for Virulence of Leishmania donovani , 2011, Infection and Immunity.

[111]  M. Morris,et al.  Glycolysis in the African Trypanosome: Targeting Enzymes and Their Subcellular Compartments for Therapeutic Development , 2011, Molecular biology international.

[112]  Yves Pommier,et al.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.

[113]  F. Chappuis,et al.  NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness , 2010, PLoS neglected tropical diseases.

[114]  C. Carrillo,et al.  Trypanosoma cruzi amino acid transporter TcAAAP411 mediates arginine uptake in yeasts. , 2010, FEMS microbiology letters.

[115]  I. Coppens,et al.  A high‐affinity putrescine‐cadaverine transporter from Trypanosoma cruzi , 2010, Molecular microbiology.

[116]  S. Valentini,et al.  Functional significance of eIF5A and its hypusine modification in eukaryotes , 2010, Amino Acids.

[117]  W. Hunter,et al.  Structure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the Leishmaniases† , 2009, Journal of medicinal chemistry.

[118]  R. Madhubala,et al.  Identification and Characterization of a Novel Deoxyhypusine Synthase in Leishmania donovani* , 2009, The Journal of Biological Chemistry.

[119]  W. de Souza,et al.  Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs , 2009, Interdisciplinary perspectives on infectious diseases.

[120]  R. Barker,et al.  Trypanocidal Activity of 8-Methyl-5′-{[(Z)-4-Aminobut-2-enyl]-(Methylamino)}Adenosine (Genz-644131), an Adenosylmethionine Decarboxylase Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.

[121]  D. Rentsch,et al.  Arginine Homeostasis and Transport in the Human Pathogen Leishmania donovani* , 2009, The Journal of Biological Chemistry.

[122]  R. Balaña-Fouce,et al.  Leishmania major lacking arginase (ARG) are auxotrophic for polyamines but retain infectivity to susceptible BALB/c mice. , 2009, Molecular and biochemical parasitology.

[123]  M. Phillips,et al.  RNA Interference-Mediated Silencing of Ornithine Decarboxylase and Spermidine Synthase Genes in Trypanosoma brucei Provides Insight into Regulation of Polyamine Biosynthesis , 2009, Eukaryotic Cell.

[124]  M. Wilson,et al.  Leishmania donovani Ornithine Decarboxylase Is Indispensable for Parasite Survival in the Mammalian Host , 2008, Infection and Immunity.

[125]  M. Phillips,et al.  Regulated Expression of an Essential Allosteric Activator of Polyamine Biosynthesis in African Trypanosomes , 2008, PLoS pathogens.

[126]  M. Vannier-Santos,et al.  The putrescine analogue 1,4-diamino-2-butanone affects polyamine synthesis, transport, ultrastructure and intracellular survival in Leishmania amazonensis. , 2008, Microbiology.

[127]  H. Kaur,et al.  Validation of spermidine synthase as a drug target in African trypanosomes. , 2008, The Biochemical journal.

[128]  M. Wilson,et al.  An Effect of Parasite-Encoded Arginase on the Outcome of Murine Cutaneous Leishmaniasis1 , 2007, The Journal of Immunology.

[129]  O. Heby,et al.  Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas’ disease, and leishmaniasis , 2007, Amino Acids.

[130]  J. Min,et al.  Structure and mechanism of spermidine synthases. , 2007, Biochemistry.

[131]  M. Phillips,et al.  Allosteric regulation of an essential trypanosome polyamine biosynthetic enzyme by a catalytically dead homolog , 2007, Proceedings of the National Academy of Sciences.

[132]  D. Roos,et al.  Divergent polyamine metabolism in the Apicomplexa. , 2007, Microbiology.

[133]  A. Pegg,et al.  Polyamines and neoplastic growth. , 2007, Biochemical Society transactions.

[134]  M. Walkinshaw,et al.  The first crystal structure of phosphofructokinase from a eukaryote: Trypanosoma brucei. , 2007, Journal of molecular biology.

[135]  L. Marton,et al.  Leishmania donovani Polyamine Biosynthetic Enzyme Overproducers as Tools To Investigate the Mode of Action of Cytotoxic Polyamine Analogs , 2007, Antimicrobial Agents and Chemotherapy.

[136]  Frédéric Bringaud,et al.  Metabolic functions of glycosomes in trypanosomatids. , 2006, Biochimica et biophysica acta.

[137]  R. Madhubala,et al.  Antileishmanial Effect of 3-Aminooxy-1-Aminopropane Is Due to Polyamine Depletion , 2006, Antimicrobial Agents and Chemotherapy.

[138]  Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[139]  G. E. Cánepa,et al.  Molecular and functional characterization of a spermidine transporter (TcPAT12) from Trypanosoma cruzi. , 2006, Biochemical and biophysical research communications.

[140]  D. Rentsch,et al.  A novel high‐affinity arginine transporter from the human parasitic protozoan Leishmania donovani , 2006, Molecular microbiology.

[141]  L. Aravind,et al.  Molecular cloning, expression, and structural prediction of deoxyhypusine hydroxylase: a HEAT-repeat-containing metalloenzyme. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[142]  A. Fairlamb,et al.  Drug Resistance in Leishmaniasis , 2006, Clinical Microbiology Reviews.

[143]  B. Ullman,et al.  Identification and Characterization of a Polyamine Permease from the Protozoan Parasite Leishmania major* , 2005, Journal of Biological Chemistry.

[144]  R. Reguera,et al.  Polyamine transport in parasites: a potential target for new antiparasitic drug development. , 2005, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[145]  Xin Hu,et al.  Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo. , 2004, International journal of oncology.

[146]  D. Davies,et al.  A New Crystal Structure of Deoxyhypusine Synthase Reveals the Configuration of the Active Enzyme and of an Enzyme·NAD·Inhibitor Ternary Complex* , 2004, Journal of Biological Chemistry.

[147]  Y. Pérez-Pertejo,et al.  Mutational analysis of methionine adenosyltransferase from Leishmania donovani. , 2004, European journal of biochemistry.

[148]  K. Gibson,et al.  Arginase Plays a Pivotal Role in Polyamine Precursor Metabolism in Leishmania , 2004, Journal of Biological Chemistry.

[149]  M. Avery,et al.  Diamine derivatives with antiparasitic activities. , 2004, Bioorganic & medicinal chemistry letters.

[150]  I. Gilbert,et al.  Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. , 2003, Journal of medicinal chemistry.

[151]  C. Burri,et al.  Eflornithine for the treatment of human African trypanosomiasis , 2003, Parasitology Research.

[152]  D. Rice,et al.  Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. , 2003, Molecular and biochemical parasitology.

[153]  N. Carter,et al.  S-adenosylmethionine decarboxylase from Leishmania donovani. Molecular, genetic, and biochemical characterization of null mutants and overproducers. , 2002, The Journal of biological chemistry.

[154]  Y. Pérez-Pertejo,et al.  Cloning Expression and Characterization of Methionine Adenosyltransferase in Leishmania infantumPromastigotes* , 2002, The Journal of Biological Chemistry.

[155]  Shelly C. Lu,et al.  S‐Adenosylmethionine: a control switch that regulates liver function , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[156]  N. Biteau,et al.  Molecular characterisation of mitochondrial and cytosolic trypanothione-dependent tryparedoxin peroxidases in Trypanosoma brucei. , 2001, Molecular and biochemical parasitology.

[157]  P. Woster,et al.  Novel alkylpolyamine analogues that possess both antitrypanosomal and antimicrosporidial activity. , 2001, Bioorganic & medicinal chemistry letters.

[158]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[159]  K. Kashiwagi,et al.  Properties of a polyamine transporter regulated by antizyme. , 2000, The Biochemical journal.

[160]  S. Matsufuji,et al.  Degradation of ornithine decarboxylase by the 26S proteasome. , 2000, Biochemical and biophysical research communications.

[161]  C. Pereira,et al.  L‐Arginine Uptake and L‐Phosphoarginine Synthesis In Trypanosoma Cruzi , 1999, The Journal of eukaryotic microbiology.

[162]  I. Mathews,et al.  The crystal structure of human S-adenosylmethionine decarboxylase at 2.25 A resolution reveals a novel fold. , 1999, Structure.

[163]  A. Fairlamb,et al.  Ornithine Decarboxylase Gene Deletion Mutants of Leishmania donovani * , 1999, The Journal of Biological Chemistry.

[164]  J. Sufrin,et al.  In vivo efficacies of 5'-methylthioadenosine analogs as trypanocides , 1997, Antimicrobial agents and chemotherapy.

[165]  H. Mett,et al.  Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine , 1997, Antimicrobial agents and chemotherapy.

[166]  Martin Olivier,et al.  Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages , 1997, The EMBO journal.

[167]  R. Balaña-Fouce,et al.  Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. , 1996, Biochemical pharmacology.

[168]  S. Croft,et al.  In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors , 1996, Antimicrobial agents and chemotherapy.

[169]  V. Yardley,et al.  In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors , 1996, Antimicrobial agents and chemotherapy.

[170]  R. Kaminsky,et al.  Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). , 1995, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[171]  R. Reguera,et al.  Fluorinated analogues of L-ornithine are powerful inhibitors of ornithine decarboxylase and cell growth of Leishmania infantum promastigotes. , 1994, Life sciences.

[172]  D. V. Von Hoff MGBG: teaching an old drug new tricks. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[173]  R. Reguera,et al.  Putrescine uptake inhibition by aromatic diamidines in Leishmania infantum promastigotes. , 1994, Biochemical pharmacology.

[174]  A. Pegg,et al.  Rapid exchange of subunits of mammalian ornithine decarboxylase. , 1994, The Journal of biological chemistry.

[175]  A. Bitonti,et al.  Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor , 1992, Antimicrobial Agents and Chemotherapy.

[176]  L. Ghoda,et al.  Structural elements of ornithine decarboxylase required for intracellular degradation and polyamine-dependent regulation , 1992, Molecular and cellular biology.

[177]  A. Bitonti,et al.  Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase , 1990, Antimicrobial Agents and Chemotherapy.

[178]  M. Gramiccia,et al.  In vivo effect of eflornithine (DFMO) and some related compounds on Leishmania infantum preliminary communication. , 1989, Farmaco.

[179]  A. Cerami,et al.  Chemotherapy of trypanosomiasis: the use of guanylhydrazone compounds in the treatment of experimental murine trypanosomiasis. , 1987, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[180]  A. Fairlamb,et al.  In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. , 1987, Molecular and biochemical parasitology.

[181]  R. Balaña-Fouce,et al.  Inhibition of diamine oxidase and S-adenosylmethionine decarboxylase by diminacene aceturate (berenil). , 1986, Biochemical pharmacology.

[182]  B. Chait,et al.  Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. , 1985, Science.

[183]  A. Bitonti,et al.  Characterization of spermidine synthase from Trypanosoma brucei brucei. , 1984, Molecular and biochemical parasitology.

[184]  P. McCann,et al.  Polyamine metabolism: a potential therapeutic target in trypanosomes. , 1980, Science.

[185]  A. Ilari,et al.  Polyamine-trypanothione pathway: an update. , 2017, Future medicinal chemistry.

[186]  Chagas disease in Latin America: an epidemiological update based on 2010 estimates. , 2015, Releve epidemiologique hebdomadaire.

[187]  L. Floeter-Winter,et al.  Arginase in Leishmania. , 2014, Sub-cellular biochemistry.

[188]  D. Pace Leishmaniasis. , 2014, The Journal of infection.

[189]  V. Lutje,et al.  Chemotherapy for second-stage Human African trypanosomiasis. , 2010, The Cochrane database of systematic reviews.

[190]  Y. Pérez-Pertejo,et al.  Characterization of a methionine adenosyltransferase over-expressing strain in the trypanosomatid Leishmania donovani. , 2006, Biochimica et biophysica acta.

[191]  M. H. el Kouni Potential chemotherapeutic targets in the purine metabolism of parasites. , 2003, Pharmacology & therapeutics.

[192]  Héctor Villa,et al.  Leishmania donovani methionine adenosyltransferase. Role of cysteine residues in the recombinant enzyme. , 2003, European journal of biochemistry.

[193]  J. Champoux DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[194]  E. Gerner,et al.  UC Irvine UC Irvine Previously Published Works Title Development of difluoromethylornithine ( DFMO ) as a chemoprevention agent , 2000 .

[195]  R. Madhubala,et al.  Antileishmanial effect of a potent S-adenosylmethionine decarboxylase inhibitor: CGP 40215A. , 1996, Pharmacological research.

[196]  I. Coppens,et al.  Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei. , 1995, Molecular and biochemical parasitology.

[197]  A. Fairlamb,et al.  Metabolism and functions of trypanothione in the Kinetoplastida. , 1992, Annual review of microbiology.